PepsiCo's fizz fades as GLP-1 drugs and activist investor Elliott's targets test its snack business
- Posted on October 7, 2026
- By Business News Today
- 0 Views
- 1 min read
In brief
Generating AI summary…
PepsiCo's fizz fades as GLP-1 drugs and activist investor Elliott's targets test its snack business
PepsiCo faces challenges in achieving its growth and margin targets due to rising competition and increased input costs. The company has seen a decline in its North American business, impacting sales volumes and market share. Healthier product offerings have been introduced in response to market changes and consumer preferences. Analysts predict modest revenue growth but express concerns about long-term recovery.
